envelop
e
protein
coronavirus
small
polypeptid
contain
least
one
ahel
transmembran
domain
absenc
inactiv
e
protein
result
attenu
virus
due
alter
either
virion
morpholog
tropism
apart
morphogenet
properti
protein
e
report
membran
permeabil
activ
drug
hexamethylen
amilorid
hma
amilorid
inhibit
vitro
ion
channel
activ
synthet
coronaviru
e
protein
also
viral
replic
previous
shown
coronaviru
speci
respons
sever
acut
respiratori
syndrom
sarscov
transmembran
domain
e
protein
etm
form
pentamer
ahel
bundl
like
respons
observ
channel
activ
herein
use
solut
nmr
dodecylphosphatidylcholin
micel
energi
minim
obtain
model
channel
featur
regular
ahelic
form
pentamer
lefthand
parallel
bundl
drug
hma
found
bind
insid
lumen
channel
ctermin
ntermin
open
contrast
amilorid
induc
addit
chemic
shift
etm
full
length
sarscov
e
display
channel
activ
transient
express
human
embryon
kidney
cell
wholecel
patch
clamp
setup
activ
significantli
reduc
hexamethylen
amilorid
hma
amilorid
channel
structur
present
herein
provid
possibl
rational
inhibit
platform
futur
structurebas
drug
design
potenti
pharmacolog
target
coronavirus
famili
coronavirida
genu
coronaviru
envelop
virus
caus
common
cold
human
varieti
lethal
diseas
bird
mammal
viru
speci
genu
coronaviru
organ
group
use
genet
antigen
criteria
group
subdivid
two
group
group
includ
porcin
transmiss
gastroenter
viru
tgev
wherea
group
includ
human
coronavirus
group
also
subdivid
group
eg
murin
hepat
viru
mhv
human
coronaviru
eg
viru
respons
sever
acut
respiratori
syndrom
sarscov
group
includ
avian
infecti
bronchiti
viru
ibv
turkey
coronaviru
tcov
sarscov
produc
near
pandem
infect
case
death
worldwid
http
wwwwhoint
sarscov
enzoot
unknown
anim
bird
speci
probabl
bat
suddenli
emerg
virul
viru
human
similar
cross
animalhuman
speci
barrier
thought
occur
bovin
coronaviru
bcov
human
coronaviru
year
ago
coronaviru
interspeci
jump
anim
host
human
like
reoccur
futur
therefor
urgent
need
know
coronaviru
life
cycl
new
way
battl
infect
protect
efficaci
candid
vaccin
coronavirus
human
mainli
studi
anim
far
vaccin
enter
phase
human
trial
compound
shown
activ
sarscov
data
anim
studi
clinic
trial
studi
antivir
therapi
coronavirus
sarscov
scarc
vitro
data
show
sever
chemic
may
inhibitori
activ
clinic
trial
therapi
infect
caus
human
coronavirus
coronavirus
express
envelop
e
protein
typic
short
polypeptid
sarscov
amino
acid
long
contain
least
one
ahel
transmembran
domain
etm
sarscov
e
transmembran
domain
span
residu
approxim
residu
coronaviru
e
protein
incorpor
virion
lipid
envelop
along
spike
protein
membran
protein
protein
involv
fusion
host
membran
entri
cell
protein
import
envelop
format
bud
e
protein
essenti
vitro
vivo
coronaviru
replic
howev
absenc
result
attenu
viru
shown
sarscov
recent
use
transgen
mous
model
express
sarscov
receptor
human
angiotensin
convert
sar
coronaviru
lack
gene
e
shown
attenu
contrast
wild
type
viru
grow
central
nervou
system
coronavirus
e
protein
affect
viral
morphogenesi
ie
viruslik
particl
vlp
format
releas
inde
mutat
extramembran
domain
e
protein
impair
viral
assembl
matur
mhv
tgev
absenc
e
protein
result
blockad
viru
traffick
secretori
pathway
prevent
viru
matur
addit
aforement
role
e
protein
morphogenesi
tropism
enhanc
membran
permeabl
observ
bacteri
mammalian
cell
express
mhv
e
sarscov
e
also
report
synthet
e
protein
sarscov
mhv
ibv
vitro
cationselect
ion
channel
activ
planar
lipid
bilay
activ
shown
local
transmembran
domain
also
shown
drug
hexamethylen
amilorid
hma
amilorid
inhibit
vitro
conduct
synthet
mhv
e
e
decreas
viral
replic
mhv
infect
cell
determin
channel
activ
biolog
relev
function
must
associ
structur
organ
compat
ion
channel
togeth
electrophysiolog
studi
perform
use
complet
polypeptid
lastli
correl
inhibit
molecular
descript
drugchannel
interact
must
obtain
data
current
avail
howev
see
obtain
use
synthet
transmembran
peptid
unpurifi
synthet
e
protein
nonphysiolog
environ
use
qualit
permeabl
assay
target
hma
unequivoc
determin
fact
sarscov
etm
form
pentam
dodecylphosphocholin
dpc
perfluorooctano
pfo
micel
strongli
suggest
ion
channel
activ
coronaviru
e
protein
caus
pentamer
ion
channel
therefor
present
work
aim
use
nmr
determin
structur
pentamer
oligom
form
select
label
sarscov
etm
residu
reconstitut
dpc
micel
ii
character
interact
hma
amilorid
channel
iii
test
data
still
relev
physiolog
environ
use
patch
clamp
mammalian
cell
express
full
length
sarscov
e
structur
model
describ
channel
provid
valuabl
insight
coronaviru
envelop
ion
channel
activ
ion
select
channel
inhibit
could
serv
platform
develop
novel
antivir
drug
structur
pentamer
channel
form
transmembran
domain
sarscov
e
etm
reconstruct
sever
stage
fig
ac
first
stage
structur
etm
monom
calcul
use
constraint
deriv
noe
set
etm
monomer
conform
backbon
rootmeansquar
deviat
rmsd
less
includ
side
chain
heavi
atom
see
statist
tabl
etm
form
continu
ahelix
encompass
residu
fig
ac
includ
nand
ctermini
show
sign
termin
fray
similar
result
obtain
presenc
drug
hma
amantadin
amt
fig
latter
drug
shown
inhibit
vitro
channel
activ
transmembran
domain
sarscov
etm
flank
two
nand
ctermin
lysin
second
stage
repres
etm
conform
select
thread
pentamer
scaffold
etm
monitor
intermonom
constraint
possibl
intermonom
constraint
fig
final
use
tabl
noe
ad
sequenti
upon
fulfil
noe
next
noe
ad
ambigu
due
overlap
reson
h
h
h
c
resolv
molecular
dynam
md
energi
minim
adjust
side
chain
orient
residu
form
interhel
interfac
orient
etm
determin
use
paramagnet
probe
residu
dipolar
coupl
rdc
valid
independ
reconstruct
pentamer
etm
model
orient
etm
helic
rel
dpc
molecul
micel
determin
use
dipolar
wave
ie
oscil
longitudin
relax
proton
due
period
variabl
proxim
etm
h
n
hydrophob
paramagnet
probe
confin
dpc
environ
observ
paramagnet
relax
enhanc
pre
six
isotop
label
residu
etm
fig
compar
pre
calcul
model
accord
protocol
see
fig
good
fit
observ
expect
valu
valid
propos
orient
etm
helic
ahel
bundl
orient
confirm
observ
broaden
noesi
crosspeak
aromat
sidechain
aliphat
proton
dpc
addit
mm
shown
crosspeak
etm
nand
ctermin
residu
remain
unaffect
indic
residu
expos
aqueou
environ
consist
observ
broaden
noesi
crosspeak
coronavirus
viral
pathogen
caus
varieti
lethal
diseas
bird
mammal
common
cold
human
howev
anim
coronaviru
abl
infect
human
produc
sever
acut
respiratori
syndrom
sar
caus
near
pandem
event
like
reoccur
futur
new
antivir
strategi
necessari
small
coronaviru
protein
call
envelop
import
pathogenesi
affect
format
viral
envelop
distribut
viru
bodi
vitro
studi
shown
synthet
coronaviru
envelop
protein
channel
activ
case
inhibit
drug
hexamethylen
amilorid
amilorid
present
paper
character
structur
respons
channel
activ
also
determin
bind
site
drug
hexamethylen
amilorid
channel
shown
amilorid
mild
effect
nmr
signal
protein
valid
result
support
use
mammalian
cell
express
full
length
sarscov
e
channel
activ
inhibit
hexamethylen
amilorid
mildli
amilorid
structur
model
describ
channel
provid
valuabl
insight
coronaviru
envelop
protein
ion
channel
activ
could
serv
platform
develop
novel
antivir
drug
mm
water
solubl
paramagnet
probe
gadodiamid
ad
fresh
sampl
shown
residu
dipol
coupl
rdc
also
measur
fig
use
two
differ
polyacrylamid
concentr
method
compress
gel
subject
axial
compress
lower
densiti
allow
applic
greater
compress
forc
gel
subject
radial
compress
use
gel
press
assembl
rdc
measur
sinusoid
wave
residu
period
could
observ
residu
consist
ahel
period
rdc
residu
could
fit
period
due
either
deviat
ideal
ahel
geometri
conform
dynam
rdc
use
determin
align
tensor
helix
one
tensor
coincid
axi
symmetri
helic
bundl
consist
helix
form
part
oligomer
complex
shown
previous
techniqu
thu
summar
present
pentamer
ahel
bundl
model
built
use
noe
constraint
ii
paramagnet
relax
data
iii
obtain
align
tensoraxi
symmetri
rdc
iv
known
oligomer
size
etm
ahel
bundl
gain
insight
compact
channel
structur
monitor
deviat
observ
chemic
shift
expect
random
coil
structur
period
chemic
shift
analyz
use
wavelet
fig
residu
period
residu
per
cycl
close
helix
residu
per
turn
residu
period
residu
period
residu
per
cycl
ie
close
canon
ahelix
interpret
low
period
central
part
ahelix
due
tighter
pack
oligom
ie
lumen
orient
etm
residu
expect
experi
less
hydrophil
environ
region
less
compact
end
etm
lead
uniform
hydrophob
around
helix
lumen
pentamer
etm
assembl
fig
adopt
distinct
hourglass
shape
polar
side
chain
orient
toward
lumen
md
simul
form
ring
inner
diamet
fig
c
hydrophob
side
chain
line
spaciou
region
diamet
reach
constrict
part
locat
residu
diamet
respect
fig
c
report
drug
hma
amilorid
inhibit
vitro
conduct
synthet
mhv
e
e
close
homolog
sarscov
e
therefor
test
effect
drug
etm
channel
etm
dpc
micel
expos
hma
chang
h
n
chemic
shift
observ
throughout
peptid
affect
etm
amid
proton
cluster
end
etm
exhibit
largest
chemic
shift
fig
noe
observ
hma
etm
fig
suggest
presenc
two
bind
site
one
near
anoth
near
figur
also
show
proton
form
hma
bound
channel
form
may
stabil
hydrogen
bond
sidechain
carbonyl
guanidinium
moieti
result
observ
h
signal
ppm
tabl
absenc
etm
hma
reson
observ
ph
lower
indic
possibl
role
etm
stabil
hma
proton
state
rel
intens
crosspeak
assign
hma
proton
indic
ntermin
bind
site
near
hma
etm
stoichiometri
approach
ie
one
hma
molecul
per
etm
pentam
contrast
ctermin
bind
site
near
hma
etm
stoichiometri
suggest
site
rapid
chemic
shift
time
scale
exchang
etmbound
micellebound
form
hma
note
dpc
micel
hma
exhibit
ident
diffus
rate
indic
hma
partit
deterg
phase
shift
h
n
hsqc
spectrum
addit
hma
appar
fig
ac
amilorid
contrast
produc
signific
chemic
shift
chang
fig
bd
even
etm
drug
molar
ratio
ten
time
higher
hma
shown
comparison
addit
amt
ten
time
concentr
hma
also
produc
similar
chemic
shift
observ
hma
shown
howev
contrast
hma
noe
amt
etm
detect
interest
note
present
discontinu
point
chemic
shift
period
fig
b
also
show
significantli
broaden
crosspeak
h
n
hsqc
spectrum
due
conform
exchang
process
elev
temperatur
exchang
increas
result
sharpen
crosspeak
fig
ef
broaden
also
reduc
addit
hma
fig
g
suggest
stabil
one
etm
exchang
conform
bound
hma
incident
increas
temperatur
also
result
sharpen
crosspeak
shown
indic
residu
may
involv
hingelik
motion
propos
two
bind
site
hma
etm
channel
shown
fig
one
bind
site
hma
may
stabil
hydrogen
bond
network
asn
side
chain
cyclohexamethylen
ring
point
away
center
channel
fig
ac
second
bind
locat
hma
observ
near
cterminu
etm
around
residu
amilorid
group
hma
like
involv
interact
guanidinium
group
fig
bd
cyclohexamethylen
ring
van
der
waal
contact
methyl
group
residu
ie
orient
toward
center
membran
confirm
relev
pentamer
structur
effect
hma
amilorid
channel
activ
result
obtain
transient
express
sarscov
e
human
embryon
kidney
cell
transfect
cell
produc
significantli
higher
channel
activ
control
fig
wholecel
patch
clamp
record
fig
reveal
moder
inward
neg
current
larg
outward
posit
current
conduct
figur
show
significantli
smaller
control
current
obtain
cell
transfect
vector
alon
nontransfect
cell
acsf
artifici
cerebrospin
fluid
use
bath
solut
contain
high
concentr
nacl
mm
wherea
intern
solut
contain
high
concentr
potassium
ion
mm
close
intracellular
medium
physiolog
condit
record
condit
estim
equilibrium
potenti
e
na
e
k
mv
mv
respect
strong
select
either
cation
would
produc
revers
potenti
ie
zero
current
near
correspond
equilibrium
potenti
channel
poorli
select
revers
potenti
would
valu
somewher
e
na
e
k
wherea
select
would
produc
revers
potenti
mid
point
valu
mv
observ
valu
revers
potenti
mv
fig
indic
low
select
sodium
potassium
perhap
mild
prefer
sodium
consist
previou
result
perform
planar
lipid
bilay
synthet
e
protein
test
inhibitori
effect
hma
cell
expos
mm
hma
bath
solut
significantli
reduc
whole
cell
current
flow
sarscov
e
protein
inde
mean
peak
current
mv
reduc
unpair
ttest
fig
amilorid
contrast
reduc
mean
peak
current
although
differ
statist
signific
unpair
ttest
fig
figur
note
peak
current
transfect
cell
record
panel
b
pa
larger
panel
c
pa
attribut
differ
variat
cdna
prepar
transfect
time
record
follow
transfect
etm
pentamer
channel
etm
show
suffici
resolv
h
nmr
spectra
howev
facilit
reson
assign
unequivoc
identifi
intermonom
noe
six
label
amino
acid
chemic
incorpor
near
center
etm
ahelix
select
appropri
specif
label
facilit
predict
like
intermonom
interact
use
lower
resolut
biophys
techniqu
particular
model
reconstruct
nmr
data
consist
model
deriv
analysi
evolutionari
conserv
etm
coronaviru
envelop
protein
latter
approach
data
independ
reli
reason
assumpt
homologu
share
backbon
structur
definit
conserv
mutat
appear
evolut
destabil
correct
model
transmembran
interact
may
destabil
incorrect
low
energi
model
appear
simul
along
correct
model
mutat
act
effect
silico
filter
interhel
orient
obtain
etm
ahelic
orient
respect
lumen
etm
channel
deterg
phase
also
agreement
previou
etm
helix
rotat
orient
measur
obtain
infrar
linear
dichroism
model
show
wide
constrict
form
sidechain
probabl
wide
enough
passag
sodium
ion
suggest
repres
close
state
etm
channel
n
dipolar
coupl
six
label
backbon
amid
exhibit
period
consist
canon
ahel
period
except
found
outlier
ie
n
vector
point
direct
consist
label
residu
addit
amid
group
show
signific
line
broaden
reduc
elev
temperatur
like
due
acceler
exchang
rate
interpret
conform
exchangeinduc
transvers
relax
residu
specul
conform
dynam
may
requir
channel
function
similar
band
narrow
observ
addit
drug
hma
see
previou
report
suggest
synthet
cov
e
protein
cation
select
channel
activ
select
p
na
p
k
mhv
e
sar
cov
e
ibv
present
work
observ
mild
prefer
sodium
potassium
accord
data
appar
select
hmv
sodium
appear
signific
diamet
nake
na
around
k
diamet
etm
pore
level
suffici
accommod
singl
dehydr
na
k
ion
henc
may
specul
polar
equival
sequenc
form
select
filter
cation
equival
residu
sarscov
e
mhv
e
gln
fig
one
methylen
longer
side
chain
may
lead
occlus
channel
posit
may
explain
observ
higher
select
sodium
mhv
e
also
note
lumenfac
orient
asn
gln
may
also
structur
role
residu
known
stabil
transmembran
interact
present
work
local
two
bind
site
hma
specul
local
hma
near
could
similar
cov
e
protein
posit
lumenexpos
alway
occupi
polar
residu
cov
e
sequenc
n
q
fig
howev
hma
sensit
shown
e
protein
contain
long
polar
side
chain
posit
eg
n
sarscov
e
paper
q
mhv
e
ibv
e
contain
smaller
polar
side
chain
thr
hmainsensit
would
interest
test
e
protein
contain
small
polar
side
chain
posit
eg
gener
hma
insensit
similarli
ctermin
end
etm
posit
equival
sarscov
e
basic
residu
often
found
e
sequenc
fig
addit
hmasensit
cov
e
protein
least
one
lumenfac
residu
immedi
polar
ta
sarscov
e
mhv
e
kl
ibv
e
group
report
hma
insensit
polar
residu
posit
af
pair
note
howev
ctermin
residu
etm
may
involv
hma
bind
context
full
length
protein
experi
clarifi
point
use
extend
etm
full
length
sarscov
e
progress
cell
infect
mhv
ec
hma
mm
wherea
edelet
viru
mhvde
effect
observ
hma
addit
point
e
protein
hma
target
hma
also
inhibit
replic
cultur
cell
ec
mm
neither
case
howev
amilorid
antivir
activ
replic
cultur
cell
consist
result
show
channel
activ
transfect
mammalian
cell
express
sarscov
e
inhibit
extracellular
hma
amilorid
suggest
specif
activ
sarscov
e
plasma
membran
orient
nterminu
face
cytoplasm
wherea
cterminu
etm
would
face
extracellular
domain
latter
therefor
would
like
hma
bind
site
patch
clamp
experi
although
fact
hma
partit
deterg
micel
presum
lipid
bilay
suggest
n
ctermini
etm
could
access
drug
weak
inhibit
observ
amilorid
consist
nmr
data
addit
amilorid
etm
show
increas
line
broaden
small
chang
peak
posit
suggest
global
perturb
protein
structur
specif
interact
final
although
chemic
shift
induc
amt
shown
similar
observ
hma
observ
noe
amt
etm
unexpect
contrast
observ
lysineflank
etm
peptid
vitro
ion
channel
activ
observ
etm
without
flank
lysin
ie
like
one
use
herein
inhibit
amt
flexibl
encount
around
residu
reduc
temperatur
addit
hma
reminisc
chang
observ
influenza
channel
addit
amt
open
state
low
ph
shown
dynam
heterogen
oppos
less
flexibl
close
state
high
ph
addit
amt
caus
substanti
narrow
n
spectra
reduc
conform
distribut
ma
c
n
nmr
studi
indic
rigid
channel
presenc
drug
latter
studi
conform
model
access
sever
conform
state
amt
would
stabil
close
conform
sarscov
e
similar
rigid
etm
may
partli
respons
inhibit
although
physic
blockag
ion
passag
also
possibl
complet
etm
label
approach
progress
undoubtedli
shed
light
natur
inhibit
anoth
import
issu
effect
extramembran
domain
channel
function
stabil
exampl
proton
channel
influenza
truncat
cytoplasm
tail
alter
ion
channel
activ
express
oocyt
xenopu
laevi
analyt
ultracentrifug
show
fulllength
protein
stabil
tetram
notic
signific
larg
inward
outward
current
record
sarscov
e
protein
contrast
vector
alon
untransfect
cell
control
twotail
unpair
test
compar
vector
control
group
c
hma
mm
significantli
reduc
whole
cell
current
sarscov
e
protein
twotail
unpair
test
compar
control
plot
amilorid
mm
small
differ
control
found
statist
signific
see
text
approxim
kcalmol
sarscov
e
preliminari
sediment
equilibrium
experi
unpublish
data
suggest
slightli
lower
associ
constant
monomerpentam
equilibrium
full
length
sarscov
e
protein
synthet
etm
span
residu
k
compar
etm
k
thu
extramembran
residu
may
slightli
destabil
sarscov
e
pentam
recent
year
sever
viral
protein
shown
membran
permeabil
properti
ion
channel
activ
eg
polioviru
alphaviru
k
vpu
influenza
viru
name
collect
viroporin
howev
physiolog
relev
activ
shown
conclus
well
known
pharmacolog
target
inhibit
amt
detail
structur
avail
electrophysiolog
data
well
detail
structur
inform
lack
protein
show
present
work
sarscov
e
possess
channel
activ
vitro
also
express
mammalian
cell
structur
character
homopentamer
transmembran
domain
etm
respons
activ
solubil
dpc
micel
absenc
presenc
small
drug
although
precis
role
propos
channel
activ
known
possibl
lead
subvers
ion
homeostasi
host
cell
could
account
observ
attenu
edelet
coronavirus
see
exampl
hepat
b
viru
calcium
homeostasi
regul
hbx
protein
shown
essenti
replic
also
possibl
observ
proapoptot
effect
sarscov
e
protein
cell
could
mediat
disrupt
cell
ion
homeostasi
membran
depolar
gener
marker
apoptosi
isotop
label
amino
acid
derivat
fmoc
etm
peptid
correspond
transmembran
domain
sarscov
e
residu
e
tgtlivnsvllflafvvfllvtlailtalrnh
synthes
use
standard
solid
phase
fmoc
chemistri
intavi
respep
peptid
synthes
peptid
cleav
resin
trifluoroacet
acid
tfa
lyophil
peptid
purifi
hplc
describ
previous
lyophil
perform
presenc
hcl
molar
ratio
hcl
peptid
order
avoid
format
peptidetfa
adduct
consequ
tfa
band
cm
absent
infrar
amid
region
shown
peptid
puriti
confirm
electrospray
ioniz
esi
mass
spectrometri
etm
synthesi
nlabel
amino
acid
introduc
posit
c
nlabel
amino
acid
posit
approxim
mg
lyophil
etm
peptid
solubil
phosphatebuff
salin
pb
mm
na
hpo
nah
po
contain
mg
dpc
avanti
polar
lipid
molar
ratio
peptid
dpc
condit
sediment
equilibrium
studi
shown
etm
pentamer
amt
bind
experi
nmr
sampl
titrat
stepwis
amt
aminoadamantan
hydrochlorid
powder
fluka
dissolv
pb
ph
final
molar
ratio
peptid
dpc
amt
hma
nhexamethylen
amilorid
sigma
amilorid
amilorid
hydrochlorid
sigma
bind
experi
aliquot
hma
solubil
dmso
cambridg
isotop
amilorid
solubil
water
ad
empti
nmr
tube
case
solvent
remov
lyophil
follow
addit
etmdpc
solut
molar
ratio
peptid
dpc
drug
ie
ten
time
less
amt
see
result
mixtur
heat
min
vortex
equilibr
hour
collect
nmr
spectra
sampl
prepar
presenc
stearic
acid
desir
amount
first
dissolv
methanol
aliquot
correspond
mm
mm
mm
final
nmr
sampl
ad
empti
nmr
tube
dri
stream
dri
n
ga
nmr
sampl
contain
etmdpc
ad
nmr
tube
contain
dri
left
equilibr
hour
gadodiamid
omniscan
gadolinium
chelat
bi
amino
ethyl
amino
acet
ge
healthcar
use
stock
solut
dilut
mm
weakli
align
sampl
prepar
soak
mm
solut
select
label
etm
mm
dpc
polyacrylamid
gel
two
differ
acrylamid
concentr
axial
radial
compress
respect
use
independ
verifi
experiment
result
gel
prepar
stock
contain
wv
acrylamid
biorad
laboratori
wv
n
nmethylenebisacrylamid
biorad
laboratori
yield
acrylamidebisacrylamid
molar
ratio
acrylamid
gel
cast
mm
inner
diamet
id
glass
tube
gel
cast
gel
chamber
mm
id
new
era
enterpris
inc
complet
polymer
gel
wash
larg
excess
h
overnight
ensur
remov
unreact
compon
gel
dri
complet
peptid
solut
soak
dri
gel
overnight
ensur
complet
rehydr
gel
care
ad
mm
id
shigemi
tube
shigemi
co
ltd
compress
axial
use
suppli
shigemi
plunger
gel
radial
compress
mm
id
openend
tube
use
gel
press
assembl
new
era
enterpris
inc
secur
use
suppli
support
rod
end
gel
plug
nmr
experi
perform
use
bruker
avanceii
nmr
spectromet
equip
cryogen
probe
bruker
biospin
complet
sequencespecif
assign
backbon
h
n
achiev
use
homonuclear
h
n
h
aromat
bandselect
noesi
fig
n
resolv
noesyhsqc
c
resolv
noesyhsqc
n
hsqcnoesi
intramonom
noe
involv
backbon
sidechain
proton
assign
use
set
noesi
spectra
mix
time
noesi
spectra
set
ms
identifi
intermonom
contact
construct
differ
two
h
n
h
aromat
bandselect
noesi
spectra
acquir
without
c
decoupl
chemic
shift
evolut
period
base
reconstruct
secondari
structur
etm
noe
identifi
intermonomer
ie
h
coval
bound
proxim
h
spin
could
explain
intramonom
distanc
amplitud
intermonom
noe
use
defin
correspond
upper
limit
constraint
two
set
hma
h
reson
assign
use
tocsi
noesi
spectra
noe
etm
hma
identifi
direct
comparison
noesi
spectra
measur
without
presenc
drug
fig
orient
etm
ahelic
respect
lipid
hydrocarbon
phase
verifi
paramagnet
enhanc
induc
longitudin
h
n
relax
six
label
amino
acid
satur
recoveri
method
seri
h
n
hsqc
experi
variabl
interscan
delay
employ
use
two
differ
approach
experiment
data
obtain
compar
expect
paramagnet
relax
enhanc
pre
propos
pentamer
structur
protocol
fig
dss
sodium
use
intern
refer
h
nuclei
chemic
shift
c
n
nuclei
calcul
h
chemic
shift
n
residu
dipolar
coupl
rdc
determin
use
trosyantitrosi
spectra
acquir
data
analyz
modul
structur
etm
monom
dpc
micel
calcul
use
sitespecif
assign
h
c
n
reson
unassign
noe
input
program
cyana
structur
calcul
start
random
conform
use
standard
simul
anneal
protocol
cyana
statist
meaning
noe
distanc
constraint
final
cyana
cycl
tabl
show
high
densiti
structur
constraint
per
amino
acid
seven
cycl
noe
assign
structur
reconstruct
result
bundl
conform
averag
target
function
valu
symmetr
etm
homopentamer
structur
reconstruct
fig
ac
start
backbon
model
base
orient
data
sitespecif
infrar
dichroism
ssid
defin
helix
tilt
rotat
pitch
angl
residu
etm
ahelix
built
nmr
data
superimpos
onto
pentam
skeleton
obtain
full
atom
descript
model
model
subject
energi
minim
resolv
steric
clash
follow
interhel
noe
tabl
use
constraint
molecular
dynam
md
simul
refin
structur
interhel
noe
constraint
appli
one
one
system
reach
equilibrium
anoth
constraint
ad
upon
inclus
interhel
constraint
refin
final
model
compat
site
specif
infrar
dichroism
nmr
data
energi
minim
restrain
md
simul
perform
use
gromac
atomist
level
detail
use
oplsaa
forc
field
atom
charg
assign
basi
default
atom
charg
valu
specifi
oplsaa
forc
field
van
der
waal
interact
model
use
cutoff
distanc
simul
cell
temperatur
maintain
k
use
berendsen
temperatur
coupl
algorithm
berendsen
pressur
coupl
algorithm
appli
maintain
pressur
bar
backbon
posit
restrain
interhel
distanc
constraint
includ
ps
simul
enough
side
chain
move
conform
constraint
allow
lumen
dimens
pentamer
model
calcul
use
hole
visual
use
vmd
accord
chemic
shift
chang
observ
addit
hma
two
etm
pentamer
model
obtain
one
model
residu
chang
exposur
hma
second
model
residu
chang
dock
hma
two
model
perform
use
glide
standard
paramet
guid
noe
constraint
allow
hma
flexibl
bind
site
defin
term
two
concentr
cube
bound
box
contain
center
accept
ligand
pose
enclos
box
contain
ligand
atom
accept
pose
upon
complet
dock
calcul
best
dock
structur
chosen
use
glidescor
gscore
function
modifi
extend
version
empir
base
chemscor
function
fulllength
sarscov
e
protein
gene
clone
clonetech
vector
use
restrict
enzym
bglii
psti
ident
insert
confirm
dna
sequenc
mm
petri
dish
mg
human
sarscov
e
cdna
transient
transfect
cell
use
standard
calcium
phosphat
method
vector
also
transient
transfect
separ
experi
control
anoth
control
use
untransfect
cell
cell
grown
h
co
incub
wholecel
patch
clamp
record
voltag
uncorrect
mv
junction
potenti
actual
voltag
obtain
subtract
mv
report
valu
wholecel
current
obtain
voltag
clamp
axopatch
amplifi
axon
instrument
filter
khz
sampl
khz
access
resist
r
usual
less
mv
capacit
transient
compens
stock
solut
amilorid
hma
sigma
mm
prepar
methanol
determin
amilorid
deriv
block
sarscov
e
protein
ion
channel
conduct
cell
ion
channel
current
detect
mm
drug
dilut
bath
solut
appli
cell
access
number
protein
paper
sarscov
e
tgev
e
e
mhv
e
ibv
e
figur
build
etm
ahel
pentamer
bundl
skeleton
etm
bundl
base
orient
data
site
specif
infrar
dichroism
etm
monom
built
nmr
data
superimpos
onto
skeleton
b
obtain
full
atom
descript
model
c
figur
ab
fig
ab
etm
presenc
mm
hma
noesi
spectrum
shown
due
larg
interfer
hma
caus
spectral
overlap
ce
fig
ac
etm
presenc
mm
amt
figur
clustal
x
sequenc
align
envelop
protein
coronavirus
total
conserv
pro
residu
sarscov
e
correspond
sarscov
sequenc
group
black
group
sequenc
blue
group
sequenc
red
group
sequenc
green
access
number
indic
next
common
name
left
posit
sarscov
e
sequenc
indic
residu
expos
lumen
pore
etm
shown
yellow
background
locat
two
hma
bind
site
etm
channel
indic
red
arrow
found
mb
tif
figur
scheme
h
n
h
aromat
bandselect
noesi
experi
suitabl
detect
h
n
h
aromat
reson
membran
protein
presenc
strong
aliphat
reson
solubil
deterg
longitudin
relax
acceler
scheme
prevent
satur
longitudin
magnet
aliphat
spin
water
build
mix
period
mix
magnet
use
acceler
relax
amid
aromat
proton
steadyst
boltzmann
thermal
equilibrium
interscan
delay
radiofrequ
puls
h
n
c
appli
ppm
respect
narrow
wide
black
bar
indic
nonselect
p
rfpuls
appli
phase
x
unless
indic
otherwis
complex
shape
line
mark
h
indic
h
n
h
aromat
bandselect
ms
excit
puls
phase
q
q
cb
hz
ms
refocuss
reburp
puls
phase
q
cb
hz
center
excit
h
n
h
aromat
bandselect
puls
place
ppm
durat
strength
puls
magnet
field
gradient
pfg
appli
along
zaxi
select
g
ms
gcm
g
ms
gcm
g
ms
gcm
two
dataset
without
ccomposit
invers
puls
decoupl
puls
acquir
use
phase
q
x
q
x
q
x
q
rec
x
quadratur
detect
dimens
achiev
statestppi
method
appli
q
subtract
dataset
result
noesi
spectrum
contain
noe
stem
h
coval
bound
